Expression and Clinical Significance of IGHD in Pancreatic Cancer
1 other identifier
observational
30
1 country
1
Brief Summary
Background ： Pancreatic cancer is the most malignant tumor in the digestive system, with low level of early diagnosis and poor prognosis. There is a lack of high sensitive and specific molecular markers in the diagnosis, treatment and prognosis of pancreatic cancer. Objective： To explore the expression of IGHD in pancreatic cancer and its correlation with clinical parameters, and to explore its prognostic value in patients with pancreatic cancer. Methods： In this study, qRT-PCR was used to detect IGHD expression in peripheral blood. The expression of IGHD in pancreatic cancer and healthy individuals was compared. The PCR results were combined with clinical data of patients. To compare the expression of IGHD in different pancreatic cancer stages and evaluate whether IGHD expression in peripheral blood can be a potential biomarker for the diagnosis of pancreatic cancer, chi-square test was used to analyze the factors influencing the expression level of IGHD. Kaplan-Meier was used to analyze patient prognosis, and further Cox regression analysis was used to analyze the factors influencing patient prognosis and independent risk factors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 7, 2022
CompletedFirst Posted
Study publicly available on registry
April 14, 2022
CompletedStudy Start
First participant enrolled
May 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2023
CompletedSeptember 6, 2022
March 1, 2022
1.5 years
April 7, 2022
September 2, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.
IGHD was highly expressed in pancreatic cancer patients , but low in the healthy cancer-free patients. Patients with high expression of IGHD had lower prognosis. High expression of IGHD, T stage (T3T4), lymphatic metastasis and distant metastasis are independent risk factors for poor prognosis in patients with pancreatic cancer. Expression level of IGHD in peripheral blood cells is a potential biomarker for the diagnosis of pancreatic cancer
2022.4-2023.10
Study Arms (2)
pancreatic cancer patients
pathologically confirmed pancreatic cancer patients
healthy people
people without no neoplastic lesions and other organic diseases
Interventions
The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
Eligibility Criteria
patients with operable pancreatic cancer without other malignancies
You may qualify if:
- Patients with pathologically confirmed pancreatic cancer
You may not qualify if:
- noperable patients
- other malignant tumors
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Biospecimen
Peripheral blood from pancreatic cancer patients and healthy cancer-free patients
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Lu Y Yuhua, phd
The Affiliated Hospital of Nantong University
- PRINCIPAL INVESTIGATOR
Chen Q Qiyang, master
Nantong University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 7, 2022
First Posted
April 14, 2022
Study Start
May 1, 2022
Primary Completion
October 31, 2023
Study Completion
October 31, 2023
Last Updated
September 6, 2022
Record last verified: 2022-03